These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 24631482)

  • 21. The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.
    Andrianesis V; Doupis J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):519-39. PubMed ID: 23978089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors.
    Freeman JS
    Postgrad Med; 2013 May; 125(3):214-26. PubMed ID: 23748522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
    Handelsman Y
    Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
    Weir MR
    Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.
    Lupsa BC; Inzucchi SE
    Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
    Mazidi M; Rezaie P; Gao HK; Kengne AP
    J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis.
    Baker WL; Buckley LF; Kelly MS; Bucheit JD; Parod ED; Brown R; Carbone S; Abbate A; Dixon DL
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
    Yamout H; Perkovic V; Davies M; Woo V; de Zeeuw D; Mayer C; Vijapurkar U; Kline I; Usiskin K; Meininger G; Bakris G
    Am J Nephrol; 2014; 40(1):64-74. PubMed ID: 25059406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
    Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
    Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):647-63. PubMed ID: 24387329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
    Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
    Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.